Europe Medical Cannabis Market Registers 18.33% Year-Over-Year Growth Amid Regulatory Shifts

Market Overview

The Europe medical cannabis market was valued at USD 2,586.1 Million in 2024 and is projected to reach USD 12,652.9 Million by 2033, growing at a CAGR of 18.33% during 2025-2033. This growth is driven by increasing legalization, expanding therapeutic applications, rising patient demand, and technological advancements in cultivation and extraction. Germany currently leads the market with a significant share.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Europe Medical Cannabis Market Key Takeaways

• The Europe medical cannabis market size was valued at USD 2,586.1 Million in 2024.
• The market is expected to grow at a CAGR of 18.33% during 2025-2033.
• Forecast market size is USD 12,652.9 Million by 2033.
• Germany dominates the market with a 26.7% share in 2024.
• Growth drivers include increasing legalization, expanding therapeutic uses, and rising patient demand.
• Technological advancements in cultivation and extraction are enhancing product quality and supply.

Download a sample copy of the report: https://www.imarcgroup.com/Europe-Medical-Cannabis-Market/requestsample

Market Growth Factors

The Europe medical cannabis market expansion is largely propelled by increasing legalization and evolving regulatory frameworks across European nations. Countries such as Germany, the UK, Italy, and Spain have progressively adapted laws facilitating the accessibility of medical cannabis to a broader patient population, resulting in robust market growth. For instance, Germany, which currently holds 26.7% of the market share, legalized limited adult-use cannabis in April 2024, further simplifying access and paving the way for market expansion.

Investments in research and development play a crucial role in driving market innovation and credibility. Strategic alliances like Segra International's partnership with GreenBe Pharma enable European growers to access advanced tissue culture cannabis clones, reducing logistical and legal impediments. This fosters the development of novel therapies and product formulations addressing conditions such as chronic pain, neurological disorders, epilepsy, and anxiety.

Technological advancements in cultivation and extraction techniques contribute to superior product quality, potency, and increased yields. Innovations such as precision agriculture, hydroponics, supercritical CO2 extraction, and equipment like Cannatrol's Vaportrol® Technology significantly improve cannabinoid purity and consistency. These advancements broaden the market scope by introducing diverse, effective medical cannabis products, enhancing patient acceptance and market penetration.

Market Segmentation

By Species:

• Indica: Holds the majority market share due to therapeutic benefits and effectiveness in treating chronic pain, anxiety, insomnia, and muscle spasms. Its shorter growth cycle and higher yields support steady supply.

By Derivative:

• Tetrahydrocannabinol (THC): Dominates the derivative segment owing to its analgesic, anti-inflammatory, and muscle relaxant properties. It effectively manages chronic pain, nausea, appetite loss, and neurological disorders.

By Application:

• Cancer: Leading application segment as medical cannabis alleviates symptoms like chronic pain, nausea, and appetite loss associated with cancer and its treatments. Rising cancer incidence and medical endorsements support this dominance.

By End Use:

• Pharmaceutical Industry: Leads the market due to established infrastructure, regulatory compliance, and extensive R&D capabilities. Pharmaceutical companies drive the development of cannabis-based medications, ensuring high-quality, standardized products.

By Route of Administration:

• Oral Solutions and Capsules: Largest segment with 55.2% market share, favored for convenience, precise dosing, and consistent therapeutic effects, especially in chronic conditions like pain and epilepsy.

By Country:

• Germany: Dominates with 26.7% market share due to progressive regulatory framework, robust healthcare system, and high patient acceptance. Imports and domestic production have risen significantly.

Regional Insights

Germany is the dominant market player in Europe, accounting for 26.7% of the Europe medical cannabis market share in 2024. The country’s progressive regulations, reimbursement policies, and high patient acceptance create a trusted market environment attracting substantial investment. For example, in 2023, Germany imported 34.6 tons of cannabis, up 26.2% from 2022, with Canada as the top supplier. This strong position underpins Europe's expanding medical cannabis landscape.

Recent Developments & News

• May 2025: Curaleaf International, with Jupiter Research LLC, obtained EU regulatory approval for a portable liquid inhaler for medical cannabis delivery.
• April 2025: Aurora Cannabis launched inhalable resin cartridges in the UK, featuring strains Sourdough (indica) and Electric Honeydew (sativa).
• March 2025: Tilray launched Tilray Craft in Germany, focusing on medicinal cannabis flowers with higher THC and terpene content.
• February 2025: Canopy Growth Corporation introduced the Tweed brand in Germany, partnering with Gro-Vida S.A. for EU-grown strains.
• January 2025: Aurora Cannabis released its first German-grown medical cannabis product under the IndiMed brand.
• February 2024: Tikun Olam Europe became the first to offer medical cannabis products by prescription in Greece.

Request Customization: https://www.imarcgroup.com/request?type=report&id=3059&flag=E

Key Players

• Canopy Growth Corporation
• Aurora Cannabis Inc.
• Tilray, Inc.
• Demecan GmbH
• Panaxia Pharmaceutical Industries Ltd
• Little Green Pharma
• Cannamedical Pharma GmbH
• Sapphire Medical
• Althea Group
• Bedrocan International

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302